09:54 AM EDT, 06/24/2024 (MT Newswires) -- Novavax ( NVAX ) said Monday it has submitted an application with the European Medicines Agency for a type 2 variation of its marketing authorization for its JN.1 Covid-19 vaccine for persons at least 12 years old.

The company said the updated formula is active against circulating strains, including KP.2 and KP.3.

The company plans to provide its vaccine in unit-dose vials available for distribution in the EU for "immediate release" after approval, Novavax ( NVAX ) said.

Price: 14.23, Change: +0.23, Percent Change: +1.64